Early-Stage Anti-Inflammation drug trial halted after testing in healthy volunteers
NCT ID NCT05740280
Summary
This was the first human study of an experimental drug called iCP-NI, designed to block inflammation at the cellular level. Researchers tested single and multiple doses in 24 healthy adults to check for safety, side effects, and how the body processes the drug. The study was terminated early, and no results about effectiveness in treating diseases are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Labcorp Clinical Research Unit Inc.
Daytona Beach, Florida, 32117, United States
Conditions
Explore the condition pages connected to this study.